Phase 0 clinical trials: Theoretical and practical implications in oncologic drug development by Coloma, P.M. (Preciosa)
© 2013 Coloma. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Open Access Journal of Clinical Trials 2013:5 119–126
Open Access Journal of Clinical Trials Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
119
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OAJCT.S32978
Phase 0 clinical trials: theoretical and practical  
implications in oncologic drug development
Preciosa M Coloma
Department of Medical informatics, 
erasmus MC University Medical 
Center, Rotterdam, The Netherlands
Correspondence: Preciosa M Coloma 
Department of Medical informatics,  
erasmus MC University Medical  
Center, Postbus 2040, 3000 CA,  
Rotterdam, The Netherlands 
Tel +31 10 704 4128 
Fax +31 10 704 4722 
email p.coloma@erasmusmc.nl
Abstract: Drug discovery and development has become a risky, expensive, and protracted 
process, with the cost of introducing a new drug to the market going as high as US$2 billion 
and the entire process taking at least 10–15 years. Great advances in biomedical research in 
recent years have not resulted in translation into medical product development, and there has 
been substantial decline in both new drug applications and biological license applications. To 
address this so-called “pipeline problem,” both the US Food and Drug Administration and its 
European counterpart, the European Agency for the Evaluation of Medicinal Products (now 
European Medicines Agency) endorsed the concept of Phase 0 studies (also known as explor-
atory investigational new drug studies), aimed towards identifying, early in the process of drug 
development, viable candidates and eliminating those lacking promise. Primary study endpoints 
of trials conducted under an exploratory investigational new drug can include evaluation of ana-
logs for lead selection, modulation of a molecular target in vivo, whole-body imaging for tissue 
distribution/target binding affinity, and agent pharmacokinetics. Phase 0 trials bridge the gap 
between traditional preclinical testing and clinical studies and are intended to provide a better 
understanding of a new compound’s pharmacokinetics, pharmacodynamics, and target localiza-
tion before initiation of Phase I trials. When such information can be obtained earlier, decisions 
regarding drug development can also be made at an earlier point in time, potentially reducing 
costs of initial preclinical studies and time-to-first-in-human testing. This review provides an 
overview of the various conditions that have to be met in order for a Phase 0 trial to be success-
ful, citing examples of two candidate drugs that have been further developed after Phase 0 trials 
in oncology. Challenges and opportunities with Phase 0 trials are discussed, including ethical 
issues associated with trials that have no therapeutic or diagnostic intent.
Keywords: pre-Phase I studies, exploratory IND, microdosing, oncology, cancer drug 
development
Background
The existing paradigm of drug discovery and development has become such an expen-
sive and protracted process: the average cost of introducing a new drug to the market, 
including the cost of failures, has been estimated to be between US$800 million and 
US$2 billion.1–3 The entire process usually takes at least 10–15 years. For anticancer 
drugs in particular, the failure rate is around 90%.4 Promising candidate agents undergo 
a series of testing, initially in vitro using models that permit evaluation of receptor 
binding, effects on enzyme activities, toxic effects, and other in-vitro pharmacologic 
parameters (see Figure 1). Candidates that are not rejected during these early investi-
gations subsequently undergo in-vivo testing for efficacy and safety. Further efficacy 
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testing can be carried out in animals, and animal studies can 
provide substantial evidence of product effectiveness under 
the following circumstances.5
1. There is a reasonably well understood mechanism for the 
toxicity of the agent and its amelioration or prevention 
by the product.
2. The effect is demonstrated in more than one animal 
species expected to react with a response predictive for 
humans, unless the effect is demonstrated in a single 
animal species that represents a sufficiently well char-
acterized animal model for predicting the response in 
humans.
3. The animal study endpoint is clearly related to the desired 
benefit in humans, generally the enhancement of survival 
or prevention of major morbidity.
4. The data or information on the kinetics and pharmaco-
dynamics (PDs) of the product or other relevant data or 
information, in animals and humans, allows selection of 
an effective dose in humans.
Pharmacokinetic (PK) and PD data obtained from animal 
models may not always be predictive of human PKs/PDs, 
which makes the early phase of drug development tricky, 
risky, and expensive: this largely determines whether a new 
molecular entity is “druggable,” ie, how likely it is able to 
modulate a target.6
Exploratory investigational new 
drug (IND) studies
Despite the huge advances in biomedical research worldwide, 
translation into medical product development has not been 
forthcoming. Recognizing this gap, the United States Food 
and Drug Administration (FDA) in its 2004 Critical Path 
Report: Innovation or Stagnation7 lamented the substantial 
decline of new drug applications and biologic license appli-
cations submitted to the agency and sought to address this 
so-called “pipeline problem.” As a follow-through to this 
imperative to provide better tools and an insightful knowledge 
base to make drug development more efficient, the US FDA 
issued, in 2006, a Guidance on Exploratory IND Studies.8 
Developed in conjunction with the pharmaceutical industry 
and the National Cancer Institute, this Guidance pointed out 
the existence of exploratory approaches consistent with regu-
latory requirements that maintain human subject protection 
while involving fewer resources than is usual with traditional 
early Phase trials. Investigators and sponsors have apparently 
underutilized these, but the US FDA believed such approaches 
could streamline the development of promising candidates. 
In a similar move earlier in 2003, the European Agency 
for the Evaluation of Medicinal Products (now European 
Medicines Agency [EMA]) released a position paper on the 
nonclinical safety studies needed to support human clinical 
Lead discovery Preclinicaltesting Phase I Phase II Phase III Phase IV
~5–6 years
~8–10 years
NDA Review
and Approval 
Target
identification 
Synthesis
Target validation
Lead optimization
IND
application 
Laboratory and animal
studies 
Clinical (in-human) studies
Figure 1 Overview of the traditional process of new drug development.
Notes: During new drug development, large numbers of compounds are generated with the aim of identifying the most promising candidates for further development. 
Promising candidates, generally structurally related, are often selected using in-vitro testing models that examine binding to receptors, effects on enzyme activities, or toxic 
effects. Candidates not rejected in these initial assessments subsequently undergo testing for efficacy and safety in animals, usually in rats and dogs. These animal studies are 
designed to permit selection of a safe starting dose for humans (including estimation of the margins of safety between clinical and toxic dose), to predict pharmacokinetic/
pharmacodynamic parameters, and to gain an insight as to which organs may be the subject of toxicity. Animal studies can provide substantial evidence of product effectiveness 
under certain circumstances.
Abbreviations: iND, investigational new drug; NDA, new drug application.
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trials with a single dose of a pharmacologically active com-
pound using microdose techniques (CPMP/SWP/2599/02/). 
A related concept paper released by EMA later in 2006 
recommended the drafting of a guidance document detailing 
what nonclinical data are required to be included in a clinical 
trials application for an early Phase I study in humans. This 
guideline was intended to allow for flexibility of approaches, 
including those outlined in the EU Microdose guideline or 
the US FDA exploratory IND guideline.9 Whereas the US 
FDA’s guidance did not constitute a new regulation (it was 
presented as an interpretation of existing recommendations 
on drug development), EMA’s position paper introduced the 
possibility of a reduced preclinical safety package for sub-
pharmacological (micro) dose clinical studies. As described 
by EMA, microdose studies can be valuable in the evaluation 
of human plasma PKs as well as receptor selectivity profile 
of candidate drugs as early as possible in the preclinical 
stage of development. Theoretically, microdose trials could 
bring about an early decision with respect to distinguishing 
between promising and inappropriate molecules for further 
development. (This EMA position paper was later superseded 
by the ICH [International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals 
for Human Use] guideline M3[R2]).10
Exploratory IND studies refer to clinical trials that 
involve very limited human exposure and have no thera-
peutic or diagnostic intent.8 The preclinical pharmacology 
and toxicology testing required for an exploratory IND is 
less extensive than that for a traditional IND, and there are 
differences in the preclinical and clinical study pathways 
for traditional and exploratory IND applications. Primary 
study endpoints of trials conducted under an exploratory 
IND can include:11 1) evaluation of analogs for lead  selection; 
2) verification as to whether a mechanism of action defined 
in experimental systems can also be observed in humans 
(eg, a binding property or inhibition of an enzyme); 3) whole-
body imaging for tissue distribution and target binding affin-
ity; and 4) agent PKs.
Phase 0 trials
Because exploratory IND studies refer to clinical trials that 
are conducted early in Phase I, such studies have been sub-
sequently dubbed “pre-Phase I studies” or “Phase 0 trials.” 
Phase 0 trials bridge the gap between traditional preclinical 
testing and clinical studies and are intended to provide a bet-
ter understanding of a new compound’s PKs, PDs, and target 
localization before initiation of Phase I trials. When such 
information can be obtained earlier, decisions regarding drug 
development can also be made at an earlier point in time.12 
Thus, Phase 0 trials, when optimized, may reduce costs of 
initial preclinical studies and time-to-first-in-human testing.
Phase 0 and Phase i – what’s the 
difference?
Phase 0 trials are not intended to impart evidence of efficacy; 
neither should they be seen as a substitute for Phase I stud-
ies that further investigate safety and tolerability at multiple 
doses. Figure 2 summarizes the main differences between 
Phase 0 and Phase I trials. While the primary goal of a Phase I 
trial is to establish the maximum tolerated dose for a com-
pound, a Phase 0 trial’s primary aim is target modulation. As a 
consequence of this, dosing and dose escalation are limited in 
Phase 0 trials. Historical guidelines recommend that the start-
ing dose for Phase I clinical trials in oncology, for example, 
be one-tenth of that dose which causes severe toxicity or 
death (STD) in 10% of animals – generally rodents – (one-
tenth the STD
10
; in mg/m2), provided that this dose does not 
cause severe, irreversible toxicity in the other mammalian 
(non-rodent) species tested.13,14 The starting dose for Phase 
0 trials with a PK or PD endpoint is generally 1/50th the rat 
“no observed adverse effect level” (NOAEL). For studies 
that do not focus on a PD endpoint, the dose selected should 
allow a substantial margin of safety (eg, a dose 100 × higher 
did not cause toxicity in the single-dose toxicity study). Thus, 
the Phase 0 maximum dose can be that at which a PK/PD 
response is observed or target modulation is measured, as 
long as no drug-associated toxicity is found, and/or that the 
dose is less than one quarter of the rat NOAEL, or that the 
total exposure to drug measured in human blood samples 
(ie, area under the curve) up to half of that measured in the 
most sensitive species.8 At this point it is necessary to empha-
size that a distinction has to be made between studies admin-
istering microdoses (such studies assess drug PK parameters: 
binding affinity and absorption; distribution; metabolism; 
and excretion) and those administering pharmacologically 
active but subtherapeutic doses (which assess more specific, 
predefined PK/PD endpoints). Moreover, because of the 
relatively small amount of study drug necessary to conduct 
a Phase 0 trial, there is no requirement for a full-scale CGMP 
(clinical good manufacturing practice)-grade commercial 
manufacturing prior to trial start.4
Due to the proof-of-concept nature of Phase 0 studies, the 
number of trial participants is smaller than that for Phase I, 
usually 10 to 15 subjects. This reduced sample size has further 
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implications on the assessment of PK/PD endpoints insofar as 
the statistical analysis, choice of PD assay, and intra-patient/
inter-patient variability are concerned. With Phase 0 trials, 
patients are exposed to lower doses of the drug than in tra-
ditional Phase I trials, thus the associated risk of toxicity is 
likewise lower. While eligibility and profile of participants in 
Phase 0 and Phase I may not necessarily be different, ethical 
concerns regarding informed consent are certainly not the 
same due to the lack of therapeutic intent in Phase 0 studies. 
(Ethical considerations are discussed in another section.)
Phase 0 trials obviously have their merits, but not all 
novel agents are appropriate for Phase 0 testing. Phase 
0 studies are intended to provide flexibility in the drug 
development process, particularly for drug and biological 
Primary goals: to
evaluate mechanism
of action/target
modulation; assess
PK/PD relationships;
optimize target assay  
Involves  ~10–15
patients   
No therapeutic intent 
Limited dosing, only
to achieve target
modulation, thus less
risk of  toxicity  
Requires
incorporation of
biomarker assays/
imaging studies  
Phase 0 
Primary goal: to
determine maximum
tolerated dose (MTD)  
Involves ~20–80
patients
No therapeutic
benefit expected, but
may enable
continued evaluation
if there is evidence of
clinical response
Multiple dosing and
dose escalation
aimed at establishing
safety and toxicity
Biomarkers/imaging
studies not required
since  less focus on
PD markers
Phase I 
Figure 2 Phase 0 versus Phase i studies.
Abbreviations: PD, pharmacodynamic; PK, pharmacokinetic.
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products meant to treat a serious or life-threatening illness.8 
In the traditional Phase I trial for oncologic agents as well 
as other therapeutic areas, preliminary safety pharmacology 
studies are conducted to evaluate the systemic effects of a 
new agent on the cardiovascular system, central nervous 
system, and respiratory system; such studies can be con-
ducted as part of later animal studies. Single-dose (acute) 
toxicology studies are required in two mammalian species to 
determine toxic and safe doses. In oncologic trials, detailed 
clinical observations following dosing and appropriate elec-
trocardiographic measurements in non-rodents are generally 
considered sufficient.15 On the other hand, the US FDA may 
not require safety pharmacology studies for a Phase 0 trial 
if it involves a single microgram-quantity dose for imaging 
or PK analysis.
Proof-of-concept
The adenosine diphosphate (ADP)-ribose polymerase 
inhibitor ABT-888 (veliparib) is one of the first com-
pounds that followed the Phase 0 trial paradigm. The Phase 
0 trial was conducted by a team of investigators from 
Abbott Laboratories and the National Cancer Institute.16,17 
Preclinical data showed that tumor poly (ADP-ribose) poly-
merase (PARP) inhibition was the target of ABT-888 and a 
validated assay was available. Furthermore, at preclinical 
evaluation, efficacy of ABT-888 was demonstrated at con-
centrations that inhibit tumor PARP but which do not mark-
edly increase the agent’s toxicity. Thus, it was reasonable to 
conduct a Phase 0 study that would be aimed at evaluating 
the mechanism of action at doses that posed minimal risk of 
toxicity to human subjects.16 The ABT-888 study enrolled 14 
adult patients with advanced malignancies (or chronic lym-
phocytic leukemia and follicular lymphoma) refractory to at 
least one line of standard treatment. Patients with primary 
brain tumors, brain metastases, or a history of seizures were 
excluded because high-dose ABT-888 was found to cause 
seizures in a preclinical animal model. Prior antineoplastic 
therapy must have been completed at $2 weeks prior to 
study enrollment.17
ABT-888 fit the profile of an ideal Phase 0 agent: the target 
could be monitored, the biomarker could be assayed with 
validity and reproducibility, and its PKs appeared linear.17,18 
The ABT-888 Phase 0 study addressed two fundamental 
questions that had to be satisfied in order to proceed with 
drug development: 1) whether or not the target plasma con-
centration is achievable with oral dosing; and 2) whether or 
not tumor biopsies are able to provide definitive results after 
a single dose of the investigational agent.
Another example – and at the other end of the spectrum – 
is that of SR13668, an orally active AKT pathway inhibitor, 
which has demonstrated cancer chemopreventive potential in 
preclinical studies. The emerging field of chemoprevention 
agents encounters important barriers in development, includ-
ing larger-scale clinical trials (such agents being typically 
intended for chronic use by healthy individuals), lengthy 
time frames between discovery and approval, liability risks 
(because they are given to healthy individuals), and a growing 
funding gap for early-stage candidates.19,20 Chemopreventive 
agents derived from dietary sources in particular provide an 
excellent opportunity for Phase 0 evaluation, because such 
agents need to have a relatively wide therapeutic window. 
AKT is an anti-apoptotic proto-oncogene whose overexpres-
sion is hypothesized to be an early event in carcinogenesis, 
based on immunohistochemical analyses detecting phospho-
AKT in premalignant lung and colon lesions, with minimal 
or no expression in surrounding normal tissues.21,22 A Phase 0 
chemoprevention trial enabled the rapid identification of a 
lead formulation of SR13668 for further clinical testing. 
Healthy adult volunteers were randomly assigned to receive 
a single oral dose of SR13668 in one of five different for-
mulations (selection of the appropriate reference formulation 
was based on previous animal studies). Blood samples were 
obtained pre- and post-agent administration for PK analyses, 
with the area under the plasma concentration–time curve 
being the primary endpoint.23
The two novel compounds cited above show the feasibil-
ity of the Phase 0 paradigm, but earlier examples indicate that 
the idea behind Phase 0 studies has been around even before 
the US FDA (and EMA) guidance documents.24–28 It remains 
clear, however, that in Phase 0 trials, study design must 
integrate measures to quantify drug effect (eg, a PD assay of 
whether the agent inhibits a specific enzyme) to allow rational 
decisions about further drug development.29 It is important to 
note that the presence of a validated assay for experimental 
drug activity should not be misconstrued as presence of a 
validated biomarker.
Two other areas where Phase 0 trials may prove invalu-
able for drug development are studies combining molecu-
larly targeted drugs and for clinical trials of molecular 
imaging agents. The opportunity to administer two or more 
experimental or US FDA-approved drugs while collect-
ing appropriate PK data will contribute significantly to a 
better understanding of the bioavailability of these agents. 
The potential to correlate PK and PD data allows further 
assessment and substantiation of any synergistic activity 
with minimal risk to patients from combination toxicity; 
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hence, optimal relative doses and dosing schedules can be 
determined prior to toxicology and tolerability assessment 
in Phase I testing.11
Ethical considerations
In an earlier editorial discussing the ethics of Phase 0 trials, 
Hill emphasized that while both scientific validity and benefit 
to participants are necessary conditions justifying participa-
tion of human subjects in clinical research, only benefit (but 
not scientific validity) is considered a sufficient condition.30 
The term benefit in clinical research can mean benefit that 
is direct, indirect, or “to others.” Given the design and 
purpose of Phase 0 trials, it seems that “benefit to others” 
is the singular possible benefit expected, underlining the 
ethical challenge that such trials are up against, particularly 
with respect to the fundamental principle that the interests 
of human subjects must always take precedence over the 
interests of society.31 Since Phase 0 trials will definitely 
not benefit the enrolled person, the standard of information 
disclosure is more stringent, conforming to the “reasonable 
volunteer” standard stated in the Belmont Report on Ethical 
Principles and Guidelines for Research Involving Human 
Subjects. The “reasonable volunteer standard” is where 
the nature and amount of information is enough to enable 
the persons volunteering for research to know that the trial 
intervention is neither necessary for their care, nor is the 
intervention fully understood as a form of therapy, so that 
they can decide whether they want to participate or not.32 
The participant should have no “false hopes” of the trial 
intervention working for the benefit of the participant; that 
is, therapeutic misconception is a valid point, which needs 
to be made clear to the participant.
Phase 0 trials involving healthy volunteers can also be 
considered, from an ethical point of view, a special case of 
the healthy volunteer studies of Phase I. What seems to be 
more controversial is the issue of studies aimed at establish-
ing dose and proof of concept in the setting of oncologic 
drugs. Most Phase 0 oncology trial participants are likely 
to be drawn from the same population as Phase I subjects, 
and while they indeed comprise a vulnerable population, 
these patients are capable of understanding and appreciat-
ing information and expressing voluntary preferences in 
the context of non-beneficial research with more-than-
minimal risk.33–35 Experience with the ABT-888 Phase 0 
trial showed that patients and patient advocates are gener-
ally supportive of efforts to speed up the drug development 
process.36 Nevertheless, there can be situations described as 
confusing “aspiration with self-interest”, where prospective 
trial subjects having the disease of interest believe that 
participating in the study will advance the development of 
drugs that they might later receive;37 investigators should 
be clear about this issue at the outset. Investigators need to 
be forthright in discussing with prospective participants the 
nontherapeutic nature of Phase 0 trials, the purpose of such 
trials, as well as the potential implications on the develop-
ment of the investigational drug. Informed consent for 
study participants should make explicit that the dose of the 
investigational agent to be administered is lower than that 
which would be expected to lead to therapeutic benefit – or 
cause appreciable toxicity.
This ethical constraint of providing a microdose interven-
tion with no anticipated clinical benefits is much less chal-
lenging in chemoprevention trials, which generally exclude 
patients with cancer or other unstable medical conditions.23 
Thus, Phase 0 trials can bring opportunities to acceler-
ate chemoprevention agent development under this novel 
paradigm.38 Because fewer toxicologic data are required for 
Phase 0 trials, there is also concern that such limited toxicol-
ogy might be insufficient and may compromise patient safety, 
despite the very low dose and limited duration of exposure. 
It remains essential that all patients be closely monitored for 
any side effects, especially for oncologic agents, which are 
all potentially toxic. Moreover, evaluation of response to the 
agent often requires invasive procedures such as tissue biopsy 
(which may also have to be done more than once). Repeated 
assessments may be misconstrued by some as an indication 
of therapeutic benefit; the intent of such procedures should 
be made clear to patients.
Another concern for patients is the possible delay – or 
even exclusion – from future participation in certain clinical 
trials. While the duration of participation in a Phase 0 trial 
is expected to be short because of limited dosing schedules 
(∼7–14 days), this issue should be discussed with the patient. 
In addition, Phase 0 trials should be considered only for those 
patients who do not have symptoms that require immedi-
ate therapy. It is imperative that investigators advocate for 
Phase 0 trial participants to be subsequently treated – either 
with conventional treatment or on another clinical trial.
Indeed, it can be said that Phase 0 (cancer) trials are 
both ethically challenged and ethically challenging.30 The 
issue of being ethically challenged can be overcome with 
scientifically valid and rigorous methodology; the issue of 
being ethically challenging remains a hurdle in the sense 
that the best argument would be to say that there is a moral 
obligation to participate in clinical research (which remains 
controversial). The closer investigators are to satisfying these 
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two conditions, the closer society at-large is to accept the 
Phase 0 trial paradigm.
Summary and perspectives
Who will ultimately benefit from Phase 0 clinical trials? And 
are Phase 0 trials really necessary?27 As far as the US FDA and 
the EMA are concerned, (the introduction of the concept of) 
Phase 0 trials was necessary because the existing paradigm of 
drug development was based on the assumption of an investi-
gational compound’s toxicity being a function of dose as well 
as the idea of efficacy being somewhat related to toxicity.39 
It has been approximately 10 years since the introduction of 
the concept of Phase 0 trials (can be more or less, depending 
on the point of reference), but it will take some time before 
it can be concluded whether Phase 0 trials have a positive 
impact on the development of new drugs for cancer or other 
indications, independent of whether exploratory IND studies 
result in further development of promising candidate prod-
ucts or elimination of nonviable agents. The ABT-888 and 
SR13668 trials cited earlier are important examples resulting 
in the further development of these agents and can help assess 
the added value of the exploratory IND approach to the drug 
development armamentarium. A survey conducted within 
the Pharmaceutical Research and Manufacturers of America, 
published in 2010, revealed that while the pharmaceutical 
industry is still taking a circumspect approach to the Phase 0 
paradigm, the potential usefulness for early clinical guidance 
in drug development is recognized.40 It is anticipated that 
PD-driven studies will expedite the evaluation of those agents 
that directly modulate their targets. Patient safety remains 
paramount, but the emphasis of Phase 0 first-in-human testing 
is on a drug’s target rather than its toxicity.
Because drugs that fail proof-of-principle target inhibition 
studies may be discarded before reaching formal Phase I/II 
evaluation, a potential drawback of using a Phase 0 trial to 
eliminate nonviable candidate products is the premature dis-
missal of a promising candidate. This may occur for instance 
when the PKs of a microdose (as evaluated in a Phase 0 
study) does not have good correlation with the therapeuti-
cally relevant dose.11 Understanding of tumorigenesis and 
of the mechanism of targeted therapies remains inadequate, 
and so this issue may be a particularly important concern in 
oncologic drug development. The lack of reliable and vali-
dated assays (which are not readily available even for most 
approved targeted cancer drugs) could result in mistakenly 
classifying active drugs as inactive.41
A Phase 0 study is thus more valuable when consid-
ered from the point of view of a discovery, rather than a 
development tool.18 While the motivation behind Phase 0 
trials/exploratory IND is to accelerate the process of drug 
development by providing opportunities to streamline target 
identification/modulation and refine the lead optimization 
process in vivo, promising drugs will still need to be further 
evaluated for toxicity and efficacy under a traditional IND. 
Under the appropriate circumstances, Phase 0 trials may help 
to eliminate drugs that are likely to fail later-stage efficacy 
testing well before moving into trials that require large 
numbers of patients to establish drug tolerability and safety. 
The goals of this effort are to identify promising agents 
earlier, develop and establish PD assays in human samples 
prior to instituting larger trials, and potentially shorten the 
drug development timeline. Accomplishing these goals may 
then increase the success rate of new agents entering clinical 
development and bring active drugs to market faster.
Important factors that need to be considered when 
designing Phase 0 trials include: 1) evidence for linear PKs 
of the candidate drug; 2) availability of a sensitive bioassay; 
3) adequate infrastructure and dedicated and qualified 
research team; 4) availability of a measurable PD effect at 
very low doses; 5) feasibility of tumor tissue sampling vis-à-
vis ethical considerations; and 6) availability of appropriate 
trial subjects. 
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